Regenxbio (RGNX) Misses Q4 EPS by 58c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.30), $0.58 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $30.34 million versus the consensus estimate of $59.28 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Wealthfront launches custodial account with tax-gain harvesting
• Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi